Close Menu

spinout

Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.

The firm is considering separating the point-of-care and lab test arms of its business, delisting its shares, and buying back stock from shareholders.

ReadCoor is currently using its its technology to map neural circuits in the brain and has projects in the pipeline related to oncology and infectious disease.

Pages